NCT04617925: Phase 2: EMN 27 - Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- Recruiting
- Dec 9, 2020
- 1 min read
Updated: Sep 26, 2022
NCT04617925: Phase 2: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)
NCT04617925: Phase 2: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis (EMN27)
This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy.
Approximately 35 subjects will receive therapy with belantamab mafodotin. Subject participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation Phase, and a Long-term Follow-up Phase.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT04617925
Official Title: A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
First Posted : November 5, 2020
Click here to see details on ClinicalTrials.gov
Drug: Belantamab mafodotin
GSK2857916
Locations
Europe
United Kingdom
France
Germany
Greece
Italy
Netherlands